Defeng Jiao

608 total citations
9 papers, 430 citations indexed

About

Defeng Jiao is a scholar working on Immunology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Defeng Jiao has authored 9 papers receiving a total of 430 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Immunology, 3 papers in Oncology and 2 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Defeng Jiao's work include Immunotherapy and Immune Responses (3 papers), Immune Cell Function and Interaction (3 papers) and Immune cells in cancer (2 papers). Defeng Jiao is often cited by papers focused on Immunotherapy and Immune Responses (3 papers), Immune Cell Function and Interaction (3 papers) and Immune cells in cancer (2 papers). Defeng Jiao collaborates with scholars based in China. Defeng Jiao's co-authors include Xiaohu Zheng, Haiming Wei, Zhigang Tian, Binqing Fu, Rui Sun, Yiqing Shen, Yong Jiang, Yi Zhang, Peng Chen and Yeben Qian and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Immunology and Frontiers in Immunology.

In The Last Decade

Defeng Jiao

9 papers receiving 427 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Defeng Jiao China 8 215 135 124 93 68 9 430
Yufei Xing China 12 66 0.3× 132 1.0× 130 1.0× 80 0.9× 58 0.9× 34 404
Xin Lei China 13 137 0.6× 114 0.8× 109 0.9× 47 0.5× 60 0.9× 30 439
Anu Autio Finland 15 179 0.8× 143 1.1× 189 1.5× 45 0.5× 88 1.3× 26 631
Nir Rozenblum Israel 8 105 0.5× 147 1.1× 100 0.8× 75 0.8× 40 0.6× 15 479
Evan Nair‐Gill United States 11 106 0.5× 169 1.3× 129 1.0× 49 0.5× 26 0.4× 17 415
Gaurav Kumar Israel 11 67 0.3× 124 0.9× 112 0.9× 74 0.8× 68 1.0× 14 447
Yu Saida Japan 12 68 0.3× 134 1.0× 79 0.6× 53 0.6× 38 0.6× 24 282
Hao Hu China 13 82 0.4× 244 1.8× 151 1.2× 100 1.1× 176 2.6× 43 545
Hye-Yeong Kim United States 11 109 0.5× 65 0.5× 94 0.8× 44 0.5× 71 1.0× 16 361
Hong Pan China 12 132 0.6× 198 1.5× 64 0.5× 98 1.1× 85 1.3× 33 491

Countries citing papers authored by Defeng Jiao

Since Specialization
Citations

This map shows the geographic impact of Defeng Jiao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Defeng Jiao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Defeng Jiao more than expected).

Fields of papers citing papers by Defeng Jiao

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Defeng Jiao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Defeng Jiao. The network helps show where Defeng Jiao may publish in the future.

Co-authorship network of co-authors of Defeng Jiao

This figure shows the co-authorship network connecting the top 25 collaborators of Defeng Jiao. A scholar is included among the top collaborators of Defeng Jiao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Defeng Jiao. Defeng Jiao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

9 of 9 papers shown
1.
Wang, Dong, Xiaohui Li, Defeng Jiao, et al.. (2023). LCN2 secreted by tissue-infiltrating neutrophils induces the ferroptosis and wasting of adipose and muscle tissues in lung cancer cachexia. Journal of Hematology & Oncology. 16(1). 30–30. 49 indexed citations
2.
Li, Xiaohui, Li Zhou, Meijuan Zheng, et al.. (2023). Tumor-infiltrating platelets promote the growth of lung adenocarcinoma. Translational Oncology. 39. 101813–101813. 7 indexed citations
3.
Du, Xianghui, Huaiping Zhu, Defeng Jiao, et al.. (2022). Human-Induced CD49a+ NK Cells Promote Fetal Growth. Frontiers in Immunology. 13. 821542–821542. 24 indexed citations
4.
Zheng, Xiaohu, Pei Yu, Pengfei Wang, et al.. (2022). Immunomagnetic microscopy of tumor tissues using quantum sensors in diamond. Proceedings of the National Academy of Sciences. 119(5). 32 indexed citations
5.
Jiao, Defeng, Xiaohu Zheng, Xianghui Du, et al.. (2021). Immunogenic senescence sensitizes lung cancer to LUNX-targeting therapy. Cancer Immunology Immunotherapy. 71(6). 1403–1417. 5 indexed citations
6.
Zheng, Xiaohu, Defeng Jiao, Yonggang Zhou, et al.. (2020). LunX-CAR T Cells as a Targeted Therapy for Non-Small Cell Lung Cancer. Molecular Therapy — Oncolytics. 17. 361–370. 44 indexed citations
7.
Zhang, Xin, Dong Wang, Zhidong Li, et al.. (2020). Low-Dose Gemcitabine Treatment Enhances Immunogenicity and Natural Killer Cell-Driven Tumor Immunity in Lung Cancer. Frontiers in Immunology. 11. 331–331. 51 indexed citations
8.
Jiang, Yong, Xiaohu Zheng, Defeng Jiao, et al.. (2019). Peptidase inhibitor 15 as a novel blood diagnostic marker for cholangiocarcinoma. EBioMedicine. 40. 422–431. 11 indexed citations
9.
Zheng, Xiaohu, Yeben Qian, Binqing Fu, et al.. (2019). Mitochondrial fragmentation limits NK cell-based tumor immunosurveillance. Nature Immunology. 20(12). 1656–1667. 207 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026